Transdel submits Phase III topical pain drug data to FDA
The company plans to initiate randomized, double-blind, placebo controlled Phase III clinical trials for the efficacy and safety of Ketotransdel in acute pain care management, following the FDA’s
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.